Siemens Healthineers at IFCC-EFLM EuroMedLab 2019
Experience our newest innovations in Booth #51

Siemens Healthineers at IFCC-EFLM EuroMedLab 2019
Siemens Healthineers at IFCC-EFLM EuroMedLab 2019
Follow Us on Social Media

Outcomes that matter. For each patient. For every provider.

There are 7.2 billion people on Earth, and each one deserves accurate diagnostic results. Whether you need the highest immunoassay testing throughput,¹ a handheld blood gas analyzer that can deliver results in less than one minute,² a true high-sensitivity troponin I assay, one of the largest ranges of molecular assays for infectious disease testing,³ or digital and AI innovations to keep you at the forefront, Siemens Healthineers offers proven, customized diagnostic solutions that are transforming care delivery.

Because each healthcare challenge is unique—just like the patients you serve.

Join us in Booth #51 at EuroMedLab 2019 at the CCIB, Barcelona, Spain
Monday, 20 May–Wednesday, 22 May, 10:00–17:30 daily.

Educational Highlights

Educational Highlights

Industry-sponsored Workshops

Pre-registration is not required for our sponsored workshops. Workshops are open to all congress attendees on a first-come, first-served basis.

Laboratory and Clinical Practice Guides for Improved Diagnostics and Risk Outcomes Assessment: Let’s Talk about High-sensitivity Cardiac Troponin I
EDUW 8 | Monday, 20 May, 14:45-15:45 | Room 114

Chair/Moderator: Alessandro Ortisi, Siemens Healthineers

Download calendar blocker 3.7 kB

  • Introduction - Alessandro Ortisi
  • Laboratory Medicine's Role in Appropriate Clinical Utilization of High-sensitivity Cardiac Troponin Assays
    Professor Fred Apple, Hennepin Healthcare/Hennepin County Medical Center and University of Minnesota, Minneapolis, USA
  • Clinical Interpretation of High-Sensitivity Cardiac Troponin Assays in the Emergency Department
    Professor Nicholas Mills, Royal Infirmary of Edinburgh, UK
  • Q&A


This workshop will address laboratory practice recommendations for the implementation of high-sensitivity cardiac troponin into clinical practice. The role of high-sensitivity cardiac troponin will address early, rapid rule-out strategies and safety performance at 30-day outcomes as well as carefully defining and differentiating myocardial Injury and myocardial infarction along the Fourth Universal Definition of Myocardial Infarction guidelines.

Learning Objectives

  • Educate why cardiac troponin is a biomarker used to detect myocardial injury
  • Teach how to apply clinical and laboratory strategies using high-sensitivity cardiac troponin assays that will improve the ability for an early rule out of myocardial injury/infarction and early, safe discharge with substantial cost savings
  • Define a frame work for establishing high-sensitivity cardiac troponin assays into laboratories through clinical partnership and appropriate test utilization, with the goal of improving patient outcomes

Transforming Care Delivery with the Ultimate Core Laboratory
EDUW 13 | Monday, 20 May, 16:00-17:00 | Room 114

Chair/Moderator: Jean-Charles Clouet, Siemens Healthineers

Download calendar blocker 3.1 kB

  • Introduction – Jean-Charles Clouet
  • Optimization of Lab Operations to Deliver More with Less
    Dr. José Luis Bedini, Head of Center Core Laboratory, Biomedical Diagnostic Center (CDB), Hospital Clínic de Barcelona, Spain
  • Multi-Site Performance Evaluation of Assays on the Atellica Chemistry and Immunoassay Analyzers
    Dr. Antonio Buño Soto, Hospital Universitario La Paz, Madrid, Spain
  • Q&A



Today, clinical decisions rely on laboratory results more than ever before. However at the same time, laboratories are under increasing pressure to expand their capabilities by processing higher workloads faster and more predictably, reducing downtime and expanding test menus to meet clinicians’ needs. Conversely, reduced reimbursements and scarcity of qualified laboratory professionals require labs to become more efficient by reducing costs, using fewer staff, reducing their turnaround time, better managing requests for STAT testing and maximizing the productivity of every square meter of space. In this challenging environment, laboratories have to find innovative solutions to “do more with less” and which will enable them to transform care delivery to provide better patient care and outcomes.

Learning Objectives

  • Understand how laboratories can improve productivity by focusing on automated and value-add activities
  • Learn how to successfully combine a STAT laboratory with routine work
  • Learn how to design experiments and metrics to assess new instruments and reagents performances in real-world lab environments

Evolving Role of Biomarkers in Prenatal Care
EDUW 23 | Tuesday, 21 May, 14:45-15:45 | Room 114

Chair/Moderator: Edith Rojas-Kenney, Siemens Healthineers (USA)

Download calendar blocker 4.6 kB

  • Introduction – Edith Rojas-Kenney
  • Dr. Eduard Gratacós, Director and Professor at BCNatal Maternal-Fetal Medicine at Hospital Clínic and Hospital Sant Joan de Déu, University of Barcelona, Spain
  • Dra. Maria Luisa Hortas, Hospital Costa de Sol, Marbella, Spain
  • Q&A



Prenatal care plays an integral role in ensuring the health and well-being of both mother and child. Biomarkers play an important role in monitoring pregnancies to provide efficient prenatal risk assessment and to facilitate early detection of preeclampsia. Prenatal screening for Down syndrome (trisomy 21) is well established and widely used globally. It is used to establish an overall risk score based on several factors: the mother’s age at the projected time of birth, ultrasound measurement of fetal nuchal translucency (NT), and serologic measurement of pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (fβhCG) serum. Maintenance of high standards of both ultrasound and first trimester biochemistry is crucial for the quality of screening. The development of new techniques such as non-invasive prenatal testing (NIPT) offer additional screening options for aneuploidies.

The rapid and accurate diagnosis and prognosis of preeclampsia (PE) is essential for best clinical practice and maternal/fetal care. PE is caused by an imbalance of the pro- and antiangiogenic factors placental growth factor (PlGF) and soluble fms-like tyrosine (sFlt-1), respectively. Accumulating evidence indicates that sFlt-1 and PIGF can aid in the diagnosis as well as an aid in the prediction for PE.

Learning Objectives

  • Review current methodologies for prenatal screening
  • Understand role of biomarkers and NIPT in screening for fetal chromosomal aneuploidies
  • Discuss what is preeclampsia the role of biomarkers in its diagnosis

FLC kappa and lambda Testing in CSF to Support Diagnosis of Neurological Diseases
EDUW 28 | Tuesday, 21 May, 16:00-17:00 | Room 114

Chair/Moderator: Dr. Claus Prümper, Siemens Healthineers

Download calendar blocker 5.8 kB

  • Introduction – Dr. Claus Prümper
  • Free Light Chain kappa Index to Identify Patients with Oligoclonal Bands
    Professor Dr. Alexander Dressel, Department of Neurology, Carl-Thiem-Klinikum, Cottbus, Germany
  • Cerebrospinal Fluid Free Light Chains as Diagnostic Biomarker in Neuroborreliosis
    Dr. Harald Hegen, Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
  • Q&A 


Early treatment of multiple sclerosis or neuroborreliosis is desirable to limit neuro-degenerative activity. However, early clinical symptoms are unspecific. Imaging and laboratory diagnostic testing can aid in diagnosis.

Multiple sclerosis (MS) as well as neuroborreliosis induce an intrathecal immunoglobulin production, paralleled by an increase of free light chain (FLC) synthesis in cerebrospinal fluid (CSF).

Determination of oligoclonal bands (OCB) in CSF is part the recommended CSF test panel, which is a manual, qualitative and non-standardized method. Testing with automated FLC kappa and lambda index can aid in the early diagnosis: (1) pre-screening through the determination of FLC kappa index may help to reduce the number of OCB testing and (2) an elevated FLC lambda index points to a possible borrelia infection, which requires confirmation by specific methods for borrelia antibodies.

Learning Objectives

  • Understand how FLC kappa and lambda testing in CSF can help in diagnosis of neurological diseases
  • Learn how determination of FLC kappa index can reduce the number of OCB testing.
  • Learn about the association of FLC lambda index with neurobereliosis.

Effective Patient Management Through Early Diagnosis and Treatment
EDUW 31 | Wednesday, 22 May, 12:30-13:30 | Room 117

Chair/Moderator: Daniele Brivio, Siemens Healthineers

Download calendar blocker 7.2 kB

  • Introduction – Daniele Brivio
  • Automating A/C Ratio in Systematic Urinalysis for Early Detection of Kidney Disease
    Dr. Fernando Cava Valenciano, Director Laboratory Unilabs–BR Salud, Central Clinical Laboratory Hospital Infanta Sofia, Madrid, Spain
  • Leveraging Patient-side Testing in Emergency Medical Interventions
    Dr. Ervigio Corral Torres, Head of Department of Training and Quality Care, SAMUR-Civil Protection, Madrid, Spain
  • Q&A



The benefits of performing the A/C ratio in the systematic analysis of urine for early detection of kidney diseases, and the impact on the biochemical analysis in the laboratory, with the CLINITEK Novus® Urine Analyzer, also available on the Atellica® 1500 Automated Urinalysis System*.

The importance of conducting clinical analysis in emergency medical interventions with protocols developed by the SAMUR emergency service of the city of Madrid leveraging patient-side testing with the epoc® Blood Analysis System.

*Not available for sale in U.S. Product availability varies by country.

Learning Objectives

  • Understand the value of automating the A/C ratio in systematic urinalysis with the goal of improved overall patient management, and the impact on laboratory processes.
  • List the benefits of clinical analysis via patient-side testing to improve early patient management. Define protocols for implementation in emergency medical interventions.

View our complete list of posters at EuroMedLab

Poster Sessions are daily, 13:30-14:45


Poster No.Poster Title
M048A Statistical Analysis Solutionǂ to Measure the Impact of Sample Processing Methods on Diagnostic Laboratory Turnaround Time
Zheng L, Cockerham G, Hoffman J, Heydlauf M, Peterson D, Bhalla A.
Siemens Healthcare Diagnostics Inc., Flanders, NJ, U.S.
M073Everolimus Assay* with Automated Pretreatment for the Dimension® Chemistry Systems
Jie L, Tyler C, Samson L, Wei T.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.
M462Performance Evaluation of the New OPE-free Lithium Assay on the Atellica® CH Analyzer and ADVIA® Chemistry System
Patel D, Dai J.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.
M464Performance Evaluation of the New Emit II Plus Oxycodone Assay on the Viva-E® and AU680® Systems
Israel B, Walters A, Waggett D, Siefring GE Jr.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.
M470Development of ADVIA Centaur® XP Everolimus Assay
Casson N,1 Chuang T.2
1Randox Laboratories Limited, Co. Antrim, United Kingdom 2Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.
M471Development of ADVIA Centaur® XP Sirolimus Assay
Casson N,1 Chuang T.2
1Randox Laboratories Limited, Co. Antrim, United Kingdom 2Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.
T143Performance Evaluation of the Latex FLC kappa and lambda on the Atellica CH Analyzer
Muth D, Ehm M, Schwarz K.
Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany.
T229Diagnosing and Monitoring Diabetic Patients with Siemens Healthineers End-to-end Solution of HbA1c testing
Schimenes TV, Tyler A, Schaible C, Robinson C, Gisiora J, Navarro F, Urquhart J, Jones J.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.
T276The Importance of Health Economics Modeling in Assessing Costs of Point-of-care HbA1c Testing of Patients with Diabetes Mellitus Type II in High Income Countries
Navarro F1, Hren R2, Boltyenkov A2.
1Siemens Healthcare Diagnostics Inc., Norwood, MA, USA; 2Siemens Healthcare Diagnostics GmbH, Vienna, Austria; 3Siemens Healthcare GmbH, Erlangen, Germany
T330Performance Evaluation of the ADVIA Centaur Androstenedione Assay†
Parker L,1 Driscoll J,1 Higgins C,1 Stranz M,1 Garvey K,1 Donovan P,2 Zhao Z,1 Zheng YF,1 Clouet J.1
1Siemens Healthcare Diagnostics Inc., Newark, DE, U.S. 2Siemens Healthcare Diagnostics Inc., Walpole, MA, U.S.
T463Atellica UAS 800 Urine Sediment Analyzer Compatibility with Commercial Quality Control Materials and Urine Preservative Tubes
Das K, Lynch M.
Siemens Healthcare Diagnostics Inc., Norwood, MA, U.S.A
T471Atellica UAS 800 Urine Sediment Analyzer Performance: Determination of Normal-abnormal Threshold, Linearity Ranges, Carryover, and Effect of Sample Mixing on Cell Integrity
Das K, Lynch M.
Siemens Healthcare Diagnostics Inc., Norwood, MA, U.S.A
W217Performance Evaluation of the ADVIA Centaur Zika Test
Singh K, Arroyo J, Saxton E, Rawal D, Patibandla S.
Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.
W279Performance Comparison of the Fast Track Diagnostics Multiplex Real-time PCR Assays on Two Different Automated Molecular Platforms
Kin N1, Leidinger-Kaufmann P1, Cruz P1, Mei R2, Saikia J2, Steimer M1.
1Fast Track Diagnostics Luxembourg - a Siemens Healthineers company, Esch-sur-Alzette, Luxembourg 2Siemens Healthcare Diagnostics Inc., Berkeley, CA, U.S.
W316Performance of First Trimester Maternal Screening Biomarkers Pregnancy-associated Plasma Protein A (PAPP-A) and Free Beta Human Chorionic Gonadotropin (FBHCG) on the Atellica® IM Analyzer
Williams L,1 Poynton S,1 Graham, L,1 Wilkie M,1 Williamson E,1 Smith L,1 Rybacka A,1 Smith N,1 Zhang X,2 Meenan J,2 Lei J,3 Clouet JC.4
1Axis-Shield Diagnostics, Dundee, U.K. 2Siemens Healthcare Diagnostics Inc., Newark, DE, U.S. 3Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S. 4Siemens Healthcare SAS, Saint-Denis, France
W461Analytical Sensitivity of Urine Dipstick Leukocyte Esterase Tests
Rheinheimer G, Bethoney C, Boone J, Fox J, Stradinger J.
Siemens Healthcare Diagnostics Inc., Elkhart, Indiana, USA; Norwood, MA, USA


ǂ This solution and the Atellica® Process Manager are in development. Not available for sale. Features listed are development design goals. Future availability cannot be guaranteed.
*Under development. The performance characteristics of this device have not been established. Not available for sale. Product availability will vary from country to country and will be subject to varying regulatory requirements.
Information about this device is preliminary. Safety and effectiveness for the uses discussed have not been established. The device is under development and not commercially available. Future availability cannot be ensured.

Follow Us on Social Media

Get the latest news and updates before, during, and after EuroMedLab.

Share this page:

Product availability varies by country.

1. Atellica® Solution offers the highest immunoassay productivity per square meter versus leading IVD companies—up to 440 tests per hour—dependent upon test mix.
2. epoc® Blood Analysis System.
3. Fast Track Diagnostics assays are CE-marked for IVD use in the EU.